Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
about
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaPredicting response to epigenetic therapyRegulation of TIMP-1 in Human Placenta and Fetal Membranes by lipopolysaccharide and demethylating agent 5-aza-2'-deoxycytidineA comparison of azacitidine and decitabine activities in acute myeloid leukemia cell linesEquitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptomeAzacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell linesReassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposurePhase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.Decitabine: a review of its use in older patients with acute myeloid leukaemia.The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Demethylating Agents in the Treatment of CancerEpigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer.Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromesDownregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Mechanisms of resistance to decitabine in the myelodysplastic syndrome.Current therapy of myelodysplastic syndromesDecitabine in the treatment of myelodysplastic syndromes.Current limitations and future opportunities for epigenetic therapies.Targeting DNA methylation for epigenetic therapy.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaDownregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemiaCancer epigenetics: linking basic biology to clinical medicine.Episensitization: Defying Time's ArrowAcquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaDigging deep into "dirty" drugs - modulation of the methylation machinery.Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancerIncreased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapyHigh expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesMethylation of TFPI-2 is an early event of esophageal carcinogenesisβ-Thalassemia due to intronic LINE-1 insertion in the β-globin gene (HBB): molecular mechanisms underlying reduced transcript levels of the β-globin(L1) alleleMethylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
P2860
Q26745731-51E38A95-017B-45DC-B6DB-799445D320D9Q26851166-04D8ECBE-7C4E-4CC9-B388-58AFB9C0AABCQ27027751-6F9F0745-0D49-4258-9698-47998749CB89Q28397099-14E4AD83-224D-4BFD-A84B-B27F52CC962DQ28472733-598DF408-8185-4A41-9015-87A233B287A3Q28475641-511F430A-F169-47BB-BB7A-9D20E7A878ADQ28477342-5BFA337E-BCCF-49D9-8E08-16B0F1489D55Q28534843-0CDD4998-83F1-44BB-8207-70A9FD1BFD81Q33389485-ED6E413D-CA70-4C7F-B963-6758E66167D5Q33407030-FE3167C4-0A05-4D06-B606-36AF4CB92EB1Q33431584-3AD59616-63FE-4F5F-B0B1-79BF7A7A9AA8Q33678040-C216A68C-97D2-46FD-8183-864F064BF99BQ33771070-0B1F7D29-0D31-41B4-A660-D5E3BF935464Q33876297-7949EA7E-4168-47F9-93D4-7B9A2A329760Q33890300-691F8D95-B122-4EA7-8FED-7FC588C7067EQ33999539-86D80A41-CE49-460D-835F-F7EBC537611BQ34013796-8B794A82-EF4E-4EC4-A12D-AEBF33B06698Q34088403-B8D6A679-615A-4141-8FE6-E139FB112476Q34195077-3C20EA55-4D9F-4F6E-A6C6-7AE8E6464DEAQ34258037-F75B6364-6E1F-468D-9562-17943295A9BEQ34273735-73087CD2-D4A4-4D9D-BCE4-31348982C2A4Q34314177-AF1C997D-ADC6-4F59-88BA-AEF793B18A48Q35051937-EBBCC9AD-7986-4E07-866A-A0D7FE8A2207Q35190641-3F827042-1951-47B9-B4A4-E347077AE615Q35348043-8095C619-8B04-4C30-A6B9-03C73D0CED1DQ35726218-5A79B887-8671-49AB-BC42-78DD73FD2B4DQ35870211-55355684-51F4-4B47-8163-62CEF1B95783Q35984641-64961590-5D0B-41E0-8BAF-D7F473582749Q36266756-31A63205-BA92-40DD-AE4C-C81D1C9133A9Q36290974-95449AFB-58A7-4805-8FE4-CCE54ED3801DQ36502385-68448D78-2253-49DA-A318-4B201AEF2197Q36523796-B3C30088-0EDB-40FF-8EB8-B6F349890974Q36544042-4827CACB-FD58-48AC-81D2-CE7FA9C60834Q36545185-02AB6C86-4D56-4038-8C22-5B9D83EC5292Q36625233-5AF5470A-24A4-4FFE-9873-E16B21705147Q36654373-3EB754A1-5F0E-4D3B-80FA-2CA5F0611E46Q36848202-CEB71C7D-84AE-4C85-BA7C-D0D373AE34C9Q37091635-9F70BE81-80C7-42F0-87FE-04DE681B4ABAQ37194012-FEFA3BDA-61FB-4B29-95E8-468F5FC65560Q37257390-8081D8D7-8EFF-4D19-979B-2952E0A0CC72
P2860
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
@en
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
@nl
type
label
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
@en
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
@nl
prefLabel
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
@en
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
@nl
P2093
P2860
P1433
P1476
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
@en
P2093
Jaroslav Jelinek
Jingmin Shu
Taichun Qin
P2860
P304
P356
10.1182/BLOOD-2008-02-140038
P407
P577
2008-10-17T00:00:00Z